When Mexico joined T-MEC with the US and Canada, it signed a chapter on medicines and health supplies in the agreement. Mexico agreed to unify criteria and conducts among the three bodies that regulate the authorization, use and marketing of drugs.

The purpose was to ensure the availability of patented and generic drugs as well as homogenize the market. With this, the population could be better served from a more unified criterion.

To avoid that the Mexican pharmaceutical industry from being dominated by Asian and Indian regional investors, it will not be surprising that the harmonization of policies and procedures of the Federal Commission for the Protection against Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS), the US Food and Drug Administration (FDA) and the Canadian Agency for Drugs and Technologies in Health (CADTH) is accelerated within the framework of T-MEC.

The entry into force of the T-MEC trade agreement implied challenges and opportunities that must be addressed in a collaborative way among the multiplicity of participants in this regional market, in order to exploit the potential of the agreement as an instrument of regional economic recovery, and in the knowledge that its first review awaits us in 2026.

Related articles
A new decree modifies several aspects of the regulatory approval system for biosimilars in Mexico

Demand for similar biotherapeutic products in Latin America

A broader and stronger generic drug market is promoted in Mexico

  
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.